NCAM1 and myeloid sarcoma: Thus, the relapsed F-MS group exhibited a significantly higher frequency of CD56+ T cells compared to the relapse-free F-MS group (the mean frequency, 54.4% vs 10.8%, p = 0.0015) (Fig. 1b).